| 摘要 |
PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for increasing the maximal tolerated dose and thus the efficacy of an acetyl choline esterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of the AChEI in combination with a non-selective peripheral anticholinergic agent (nsPAChA).SOLUTION: The pharmaceutical composition is selected from combinations of an nsPAChA, which is selected from solifenacin, propiverine, oxyphencyclimine, tolterodine and the like, and an AChEI, which is selected from the group consisting of donepezil, rivastigmine and galanthamine.SELECTED DRAWING: None |
